
Researchers are turning to patient registries to fill rare-disease knowledge gaps.

Researchers are turning to patient registries to fill rare-disease knowledge gaps.

Similarities exist, but successful design requires that CROs understand the differences.

Registries could strengthen the postapproval safety net-critical in the current cautious environment.

A new paradigm that could transform a drug failure into a drug success would narrow the target population to those patients most likely to benefit from such treatment.

Published: March 1st 2011 | Updated:

Published: April 1st 2009 | Updated:

Published: August 1st 2005 | Updated:

Published: April 2nd 2005 | Updated: